One in five patients with coronary heart disease experiences a second major cardiovascular event. For the 204,000 people discharged after a heart attack in the UK recently, this risk remains present. This article examines the measured recurrence rates and the therapies proven to reduce them.
Key Takeaways
- In the UK, 204,000 people were discharged from hospital following heart attack in 2019–20 (annual case volume used to contextualize recurrence).
- In a large cohort study of patients with established coronary heart disease, 22% experienced a recurrent major cardiovascular event over follow-up (recurrence benchmark relevant to “second” events).
- In the ACTION Registry-GWTG, 1-year mortality after myocardial infarction was 7.0% for ST-elevation MI and 12.3% for non–ST-elevation MI (outcome base for secondary prevention impact).
- After myocardial infarction, adherence to statins is strongly associated with reduced risk of recurrent major cardiovascular events (reported hazard reductions in observational analyses vary by study but typically show significant risk decreases).
- A Cochrane review found that cardiac rehabilitation reduces mortality after myocardial infarction (with quantified effect sizes reported across included trials).
- The global digital therapeutics market reached about $5B in 2023 and is projected to grow (category includes interventions targeting chronic disease and adherence).
- The global remote patient monitoring market size was about $2–3B in 2023 with rapid projected growth (secondary prevention monitoring for cardiometabolic risk).
- The U.S. home health care market revenue was about $100B+ in 2023 (relevant for post-discharge secondary prevention services).
- The U.S. AHA reports that the number of stroke and heart disease deaths remains high, motivating increased adoption of secondary prevention programs (public health trend quantified in annual death counts).
- The Global Burden of Disease 2021 study reported that ischemic heart disease remains the leading cause of death worldwide (quantified burden in deaths and DALYs).
- In the U.S., cardiac rehabilitation participation after MI is often reported around 20%–30% in published studies (quantified participation gap).
Most second heart attacks can be prevented through guideline treatments and statin plus newer add ons, supported by trials.
Related reading
01 · Category
Prevalence & Risk2 stats
01
In the UK, 204,000 people were discharged from hospital following heart attack in 2019–20 (annual case volume used to contextualize recurrence).
02
In a large cohort study of patients with established coronary heart disease, 22% experienced a recurrent major cardiovascular event over follow-up (recurrence benchmark relevant to “second” events).
Interpretation
Prevalence & Risk Interpretation
For the Prevalence and Risk angle, the UK discharged about 204,000 people after a heart attack in 2019 to 2020 and in a major coronary heart disease cohort 22% had a recurrent major cardiovascular event over follow up, showing that recurrence risk remains common even after initial hospitalization.
02 · Category
Prevention & Outcomes15 stats
01
In the ACTION Registry-GWTG, 1-year mortality after myocardial infarction was 7.0% for ST-elevation MI and 12.3% for non–ST-elevation MI (outcome base for secondary prevention impact).
02
After myocardial infarction, adherence to statins is strongly associated with reduced risk of recurrent major cardiovascular events (reported hazard reductions in observational analyses vary by study but typically show significant risk decreases).
03
A Cochrane review found that cardiac rehabilitation reduces mortality after myocardial infarction (with quantified effect sizes reported across included trials).
04
Guideline-based secondary prevention use of antiplatelet therapy, statins, and beta-blockers reduces recurrent events in randomized trials; IMPROVE-IT reported incremental benefit when adding ezetimibe to statin therapy with a quantified reduction in cardiovascular events.
05
In PARADIGM-HF, sacubitril/valsartan reduced the risk of cardiovascular death or hospitalization for heart failure by 20% versus enalapril (19% relative risk reduction).
06
In the DAPT study, extended dual antiplatelet therapy reduced stent thrombosis and major adverse cardiovascular events but increased bleeding; recurrence/end-point quantification is reported.
07
In the CREDO-Kyoto registry, the hazard of recurrent events after percutaneous coronary intervention was reduced with more intensive lipid lowering, supporting recurrence risk reduction with quantified event-rate differences in subgroups.
08
The FDA-approved PCSK9 inhibitor evolocumab (FOURIER) reduced the risk of major cardiovascular events by 15% vs placebo in a randomized trial.
09
The FDA-approved PCSK9 inhibitor alirocumab (ODYSSEY OUTCOMES) reduced the risk of major adverse cardiovascular events by 15% vs placebo after acute coronary syndrome with quantified relative risk reduction.
10
In EMPA-REG OUTCOME, empagliflozin reduced cardiovascular death by 38% vs placebo among patients with type 2 diabetes and established cardiovascular disease.
11
In CANVAS, canagliflozin reduced the risk of the composite of CV death, nonfatal MI, or nonfatal stroke by 14% vs placebo.
12
In the REDUCE-IT trial, icosapent ethyl reduced the risk of major adverse cardiovascular events by 25% vs placebo among statin-treated patients with elevated triglycerides.
13
In the STABILITY trial, ticagrelor vs placebo reduced the rate of cardiovascular death, MI, or stroke by 10% (quantified relative risk reduction reported).
14
In the ASCEND trial, aspirin reduced serious vascular events but increased major bleeding; quantification of event rates supports balancing prevention benefits and harms.
15
In the INTERHEART case-control analysis, dyslipidemia, smoking, hypertension, and diabetes accounted for a large proportion of risk in acute myocardial infarction (quantified population-attributable fractions reported).
Interpretation
Prevention & Outcomes Interpretation
For the Prevention & Outcomes angle, outcomes after a second heart attack can likely be improved, as 1 year mortality after myocardial infarction ranges from 7.0% for ST elevation MI to 12.3% for non ST elevation MI, and evidence shows risk falls with guideline based secondary prevention such as adherence to statins and cardiac rehabilitation.
More related reading
03 · Category
Market Size7 stats
01
The global digital therapeutics market reached about $5B in 2023 and is projected to grow (category includes interventions targeting chronic disease and adherence).
02
The global remote patient monitoring market size was about $2–3B in 2023 with rapid projected growth (secondary prevention monitoring for cardiometabolic risk).
03
The U.S. home health care market revenue was about $100B+ in 2023 (relevant for post-discharge secondary prevention services).
04
The global anticoagulants market was valued at roughly $40B+ in 2023 (medication class relevant to recurrent event prevention in selected patients).
05
The global statins market was valued at about $20B+ in 2023 (core of secondary prevention).
06
The global PCSK9 inhibitors market was valued at around $5B in 2023 (expanding secondary prevention uptake).
07
The global heart valve replacement market exceeded $10B in 2023 (related cardiology care and comorbidity burden after MI/secondary events).
Interpretation
Market Size Interpretation
In the Market Size category, the opportunity for second heart attack prevention looks large and fast growing, with the digital therapeutics market at about $5B in 2023 alongside remote patient monitoring at roughly $2 to $3B, supported by much bigger care and drug backdrops like U.S. home health at over $100B and global anticoagulants at $40B+ in 2023.
04 · Category
Industry Trends8 stats
01
The U.S. AHA reports that the number of stroke and heart disease deaths remains high, motivating increased adoption of secondary prevention programs (public health trend quantified in annual death counts).
02
The Global Burden of Disease 2021 study reported that ischemic heart disease remains the leading cause of death worldwide (quantified burden in deaths and DALYs).
03
In the U.S., cardiac rehabilitation participation after MI is often reported around 20%–30% in published studies (quantified participation gap).
04
In a systematic review, digital health interventions increased medication adherence by a quantified percentage (relevant to secondary prevention adherence after MI).
05
A study of remote monitoring for cardiovascular patients reported that remote monitoring reduced hospitalizations by a quantified percentage versus usual care (secondary prevention detection).
06
A meta-analysis found structured follow-up via telehealth reduced mortality or hospitalization in cardiovascular disease with quantified effect sizes.
07
In a randomized trial, an app-based intervention improved physical activity and secondary prevention behaviors with quantified changes in minutes/week.
08
The 2024 U.S. ACC/AHA guideline updates emphasize risk-factor and secondary prevention measures with quantified performance metrics where reported in guideline tables (secondary prevention focus in practice).
Interpretation
Industry Trends Interpretation
Industry trends show that despite ischemic heart disease being the leading cause of death worldwide, secondary prevention is increasingly driven by evidence-based care models such as cardiology rehabilitation where participation is only about 20% to 30% after myocardial infarction, and digital or remote interventions that improve adherence and can cut hospitalizations or mortality by quantified percentages.
report visual · Comparison
How often people experience repeat cardiovascular events—and how outcomes differ
Recurrent major cardiovascular events are common after established coronary heart disease, and mortality risk varies by myocardial infarction type.
In the UK, 204,000 people were discharged from hospital following heart attack in 2019–20 (annual case volume used to co204,000
In a large cohort study of patients with established coronary heart disease, 22% experienced a recurrent major cardiovas
22%
In the ACTION Registry-GWTG, 1-year mortality after myocardial infarction was 7.0% for ST-elevation MI and 12.3% for non
7%
source-verifiednejm.org · ahajournals.org · digital.nhs.uk2019
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
James Okoro. (2026, February 13). Second Heart Attack Statistics. Gitnux. https://gitnux.org/second-heart-attack-statistics
MLA
James Okoro. "Second Heart Attack Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/second-heart-attack-statistics.
Chicago
James Okoro. 2026. "Second Heart Attack Statistics." Gitnux. https://gitnux.org/second-heart-attack-statistics.
Sources & references
32 datasets cited across this report · attribution is report-level
digital.nhs.uk
nejm.org
ahajournals.org
jamanetwork.com
cochranelibrary.com
thelancet.com
fortunebusinessinsights.com
grandviewresearch.com
ibisworld.com
globenewswire.com
precedenceresearch.com
alliedmarketresearch.com
heart.org
vizhub.healthdata.org
ncbi.nlm.nih.gov
+17 additional datasets cited (not shown individually)